46.88
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$47.62
Offen:
$47
24-Stunden-Volumen:
22.41M
Relative Volume:
1.65
Marktkapitalisierung:
$100.96B
Einnahmen:
$47.64B
Nettoeinkommen (Verlust:
$5.42B
KGV:
17.56
EPS:
2.67
Netto-Cashflow:
$13.09B
1W Leistung:
-5.50%
1M Leistung:
-11.66%
6M Leistung:
-13.41%
1J Leistung:
+7.35%
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Vergleichen Sie BMY mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
BMY
Bristol Myers Squibb Co
|
46.88 | 100.96B | 47.64B | 5.42B | 13.09B | 2.67 |
![]()
LLY
Lilly Eli Co
|
751.45 | 681.85B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
155.66 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
![]()
ABBV
Abbvie Inc
|
185.58 | 342.01B | 57.37B | 4.20B | 17.83B | 2.35 |
![]()
NVO
Novo Nordisk Adr
|
64.85 | 291.20B | 42.09B | 14.65B | 10.11B | 3.2833 |
![]()
NVS
Novartis Ag Adr
|
110.13 | 219.89B | 53.22B | 12.86B | 14.85B | 6.39 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
2023-10-20 | Fortgesetzt | UBS | Neutral |
2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
2023-03-06 | Eingeleitet | Jefferies | Hold |
2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
2021-12-17 | Eingeleitet | Goldman | Buy |
2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
2021-11-01 | Herabstufung | Argus | Buy → Hold |
2021-07-27 | Fortgesetzt | Truist | Buy |
2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2021-04-13 | Hochstufung | Truist | Hold → Buy |
2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
2020-09-29 | Eingeleitet | Berenberg | Buy |
2020-07-28 | Eingeleitet | Raymond James | Outperform |
2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
2020-02-27 | Eingeleitet | Barclays | Equal Weight |
2020-01-06 | Fortgesetzt | Citigroup | Buy |
2019-12-13 | Hochstufung | Argus | Hold → Buy |
2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
2019-05-28 | Eingeleitet | Goldman | Buy |
2019-05-20 | Herabstufung | Argus | Buy → Hold |
2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Neuroendocrine Tumor Treatment Market: Investment Analysis & - openPR.com
Bristol Myers Squibb Co. Becomes Oversold - Nasdaq
Bristol Myers Squibb Co. Named Top Dividend Stock With Insider Buying and 5.21% Yield (BMY) - Nasdaq
Urothelial Carcinoma Market on Track for Major Expansion by 2034, According to DelveInsight | Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, NektarTherapeutics, BMS, Incyte, Abbisko - Barchart.com
Improving Access to Care by Strengthening Local Health System Capacity - CSRwire
The Zacks Analyst Blog Highlights Verizon Communications, Bristol-Myers Squibb, Canadian Pacific and Nova LifeStyle - Yahoo Finance
2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb - BioSpace
Top Research Reports for Verizon Communications, Bristol-Myers Squibb & Canadian Pacific - MSN
Bristol Myers Squibb to Invest $40B in the U.S. - Contract Pharma
Advanced Renal Cell Carcinoma Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Pfizer, AbbVie, Bristol-Myers Squibb, Abbott, Takeda, Amgen, Novartis, AVEO Pharma, Calithera - The Globe and Mail
Multiple Myeloma Market Set to Grow Substantially Through 2034, DelveInsight Projects | Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharma - Barchart.com
Bristol Myers Squibb appoints new general counsel - | Governance Intelligence
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MSN
BMS Commits $40B over Five Years to U.S. R&D, Manufacturing - Genetic Engineering and Biotechnology News
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight - Benzinga
Bristol-Myers GC Hands Over Legal Department To Successor - Law360
Bristol Myers Squibb names new executive vice president By Investing.com - Investing.com Canada
Bristol Myers (BMY) Experiences Increased Bearish Activity in Op - GuruFocus
Bristol Myers (BMY) Experiences Increased Bearish Activity in Options Market | BMY Stock News - GuruFocus
Bristol Myers (BMY) Unveils $40 Billion Investment in U.S. Over Five Years | BMY Stock News - GuruFocus
Bristol Myers Squibb Appoints Cari Gallman as EVP, General Counsel and Chief Policy Officer - citybiz
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Bristol Myers (BMY) Appoints Cari Gallman as New General Counsel - GuruFocus
Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours - PMLiVE
Bristol Myers Squibb announces $40bn US investment plan over five years - Yahoo Finance
Bristol Myers Squibb names new executive vice president - Investing.com
Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer - Quantisnow
Bristol Myers to invest $40 billion in the US over 5 years | Business Information & News | FE - Westlaw Today
Bristol Myers to invest $40 billion in the US over 5 years - Reuters
Bristol Myers to invest $51.6 billion in the US over 5 years - The Straits Times
Company with deep NJ roots plans hundreds of more layoffs out of New Jersey - New Jersey 101.5
Bristol Myers to invest $40 billion in the US over 5 years, CEO says - marketscreener.com
Bristol Myers Promises $40 Billion US Investment Over Five Years - MSN
Bristol Myers Squibb Laying Off 500+ Employees From Lawrence Township Office - dailyvoice.com
Layoff Tracker: Pliant Cuts 45% of Staff To Extend Cash Runway - BioSpace
Was Jim Cramer Right About Bristol-Myers Squibb Company (BMY)? - Insider Monkey
Bristol-Myers Squibb (BMY) Faces Valuation Concerns - GuruFocus
Are Wall Street Analysts Bullish on Bristol-Myers Stock? - MSN
Jim Cramer Says He Likes Bristol-Myers Squibb (BMY) More Than Merck Due to Schizophrenia Drug - Insider Monkey
MHRA approval for BMS’ SC Opdivo - The Pharma Letter
Bristol-Myers Squibb's (NYSE:BMY) Strong Earnings Are Of Good Quality - Yahoo Finance
BMY Gains UK Approval for Faster Nivolumab Injection | BMY Stock News - GuruFocus
Piper Sandler Raises Price Target for Bristol Myers (BMY) to $66 | BMY Stock News - GuruFocus
Bristol Myers Squibb: innovating oncology care - MSN
Analysis of Cancer Immunotherapy Technologies and Global Markets to 2029 - GlobeNewswire Inc.
Is Bristol-Myers Squibb Company (BMY) the Best Long-Term Dividend Stock to Buy According to Billionaires? - Insider Monkey
BMY: Bristol Myers' Chief Medical Officer Acquires Additional Sh - GuruFocus
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock - Yahoo Finance
Our impact - Bristol Myers Squibb
Jim Cramer is Recommending This Dividend Stock With 5% Yield for ‘Good Protection’ - Yahoo Finance
HSBC Adjusts Price Target for Bristol Myers (BMY) Amid Tariff Co - GuruFocus
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):